Director/PDMR Dealing

About this update from Arecor Therapeutics Plc

Arecor Therapeutics plc   ("Arecor", the "Company" or the "Group")   Director/PDMR Dealing   Cambridge, UK, 21 May 2025. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that Andrew Richards (Chair), Sarah Howell (Chief Executive Officer) and Jan Jezek (Chief Scientific Officer) have all purchased ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares"). Details are included in the table below.   Name Number of Ordinary Shares purchased Price (£) Total beneficial interest (Ordinary Shares) Total beneficial interest (%) Andrew Richards 31,750 0.4697 318,361 0.84% Sarah Howell 21,077 0.4697 905,481 2.40% Jan Jezek 10,000 0.4700 417,808 1.11%     -ENDS-   For more information, please contact:   Arecor Therapeutics plc www.arecor.com Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060 Email: [email protected] David Ellam, Chief Financial Officer Tel: +44 (0) 1223 426060 Email: [email protected]   Singer Capital Markets Advisory LLP (NOMAD and Broker) Phil Davies, Sam Butcher Tel: +44 (0) 20 7496 3000   ICR Healthcare Chris Gardner, David Daley, Lindsey Neville Tel: +44 (0) 20 3709 5700 Email: [email protected]     Notes to Editors   About Arecor Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.  For further details please see our website, www.arecor.com         NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM      1 Details of the person discharging managerial responsibilities/person closely associated a) Name Andrew Richards 2 Reason for the notification a) Position/status Chair b) Initial notification/Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Arecor Therapeutics plc b) LEI 98450093D1213A8DDD58 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Ordinary Shares b) Identification Code GB00BMWLM973 c) Nature of the transaction Purchase of Ordinary Shares d) Price(s) and volume(s)  £ 0.4697 and  31,750 Ordinary Shares e) Aggregated information - Aggregated volume - Aggregated price N/A f) Date of the transaction 19 May 2025 g) Place of the transaction London Stock Exchange, AIM      1 Details of the person discharging managerial responsibilities/person closely associated a) Name Sarah Howell 2 Reason for the notification a) Position/status Chief Executive Officer b) Initial notification/Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Arecor Therapeutics plc b) LEI 98450093D1213A8DDD58 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Ordinary Shares b) Identification Code GB00BMWLM973 c) Nature of the transaction Purchase of Ordinary Shares d) Price(s) and volume(s)  £ 0.4697 and  21,077 Ordinary Shares e) Aggregated information - Aggregated volume - Aggregated price N/A f) Date of the transaction 19 May 2025 g) Place of the transaction London Stock Exchange, AIM      1 Details of the person discharging managerial responsibilities/person closely associated a) Name Jan Jezek 2 Reason for the notification a) Position/status Chief Scientific Officer b) Initial notification/Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Arecor Therapeutics plc b) LEI 98450093D1213A8DDD58 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Ordinary Shares b) Identification Code GB00BMWLM973 c) Nature of the transaction Purchase of Ordinary Shares d) Price(s) and volume(s)  £ 0.4700 and  10,000 Ordinary Shares e) Aggregated information - Aggregated volume - Aggregated price N/A f) Date of the transaction 20 May 2025 g) Place of the transaction London Stock Exchange, AIM  

View stock analysis, news, and events for Arecor Therapeutics Plc